Evidence map›Paper›PMID 40595830›Full record

ArticleScientific reports2025

A novel mouse model for studying complications related to type 2 diabetes using a medium-fat diet, fructose, and streptozotocin.

Yanina Luciana Mazzocco, Gastón Bergero, Sebastian Del Rosso, Zoé Magalí Cejas Gallardo, Alejandra Mariel Canalis, Ruth Eliana Baigorri, Luciana Mezzano, Juan Javier Mladin, Gustavo Tomás Díaz-Gerevini, Claudia Martínez Benavidez and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Yanina Luciana MazzoccoConsejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Centro de Investigación en Bioquímica Clínica e Inmunología, CIBICI, Córdoba, Argentina.
Gastón BergeroConsejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Centro de Investigación en Bioquímica Clínica e Inmunología, CIBICI, Córdoba, Argentina.
Sebastian Del RossoConsejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Centro de Investigación en Bioquímica Clínica e Inmunología, CIBICI, Córdoba, Argentina.
Zoé Magalí Cejas GallardoConsejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Centro de Investigación en Bioquímica Clínica e Inmunología, CIBICI, Córdoba, Argentina.
Alejandra Mariel CanalisConsejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Centro de Investigación en Bioquímica Clínica e Inmunología, CIBICI, Córdoba, Argentina.
Ruth Eliana BaigorriConsejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Centro de Investigación en Bioquímica Clínica e Inmunología, CIBICI, Córdoba, Argentina.
Luciana MezzanoUniversidad Nacional de Córdoba. Facultad de Ciencias Médicas. Instituto de Biología Celular, Córdoba, Argentina.
Juan Javier MladinHospital Nuestra Señora de la Misericordia-Nuevo Siglo, Córdoba, Argentina.
Gustavo Tomás Díaz-GereviniUniversidad Nacional de Córdoba. Facultad de Ciencias Médicas. Instituto de Biología Celular, Córdoba, Argentina.
Claudia Martínez BenavidezHospital Nuestra Señora de la Misericordia-Nuevo Siglo, Córdoba, Argentina.
Roxana Carolina CanoConsejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Centro de Investigación en Bioquímica Clínica e Inmunología, CIBICI, Córdoba, Argentina.
Maria Pilar AokiConsejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Centro de Investigación en Bioquímica Clínica e Inmunología, CIBICI, Córdoba, Argentina. pilar.aoki@unc.edu.ar.

Funding

Targeting purinergic signaling in Chagas diseaseR01AI176457 · NIAID · NATIONAL RESEARCH COUNCIL OF ARGENTINA · PI Maria Pilar Aoki · 2023 to 2026
$525k
Fondo para la Investigación Científica y Tecnológica 2019-2085National Institute of Allergy and Infectious Diseases R01AI176457NIAID NIH HHS R01 AI176457Secretaria de Ciencia y Tecnología - Universidad Nacional de Córdoba 212/20
6 · The paper itself

Abstract

The study of type 2 diabetes mellitus (T2DM) pathophysiology relies mainly on the use of animal models, the most common of which involves the consumption of high-fat diets comprising 60% calories from fat. Although these models reproduce the onset and most complications associated with T2DM, they do not accurately mimic human dietary patterns, as they lack the addition of carbohydrates such as fructose in drinking water. The aim of this study was to develop a mouse model for studying complications related to T2DM. To this end, male C57BL/6 mice were fed a medium-fat diet (34.5% kcal from fat), given 20% fructose in drinking water, and injected with a single low dose of streptozotocin (STZ; 100 mg/kg) (D + T). At week 20, D + T mice exhibited significant weight gain, elevated fasting blood glucose levels, and the development of insulin resistance compared with control mice. Furthermore, the circulating levels of liver enzymes (GPT, GOT, and alkaline phosphatase), total cholesterol, and LDL increased. Multi-organ damage, including reduced pancreatic islet size and number, severe hepatic steatosis, inflammatory infiltration in visceral adipose tissue, and cardiac and renal dysfunction, was also detected. The proposed model replicates T2DM-associated complications in young mice by combining a medium-fat diet with fructose and STZ.

Indexed as

Diabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Disease Models, AnimalFructoseStreptozocinAnimalsBlood GlucoseDiet, High-FatInsulin ResistanceLiverMaleMiceMice, Inbred C57BLBlood GlucoseFructoseStreptozocin

Identifiers

PMID40595830
PMCPMC12217141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.